Facebook Twitter Instagram
    • Home
    • About Journal
      • Aim and Scope
      • Editorial Board
      • Indexing Info
      • Contact Us
    • Browse Issues
      • Articles in Press
      • Current Issue
      • Past Issues
    • For Authors
      • Instructions to Authors
      • Article Processing Charges
      • Submit your article
      • Downloads
    Facebook Twitter Instagram
    Pharmacognosy Communications
    • Home
    • About Journal
      • Aim and Scope
      • Editorial Board
      • Indexing Info
      • Contact Us
    • Browse Issues
      • Articles in Press
      • Current Issue
      • Past Issues
    • For Authors
      • Instructions to Authors
      • Article Processing Charges
      • Submit your article
      • Downloads
    Pharmacognosy Communications
    retyeyutreu
    Editorial

    Editorial

    wadmin2By wadmin2July 9, 2018Updated:August 12, 2021No Comments2 Mins Read
    Facebook Twitter Pinterest LinkedIn Tumblr WhatsApp Email
    Share
    Facebook Twitter LinkedIn WhatsApp Pinterest Email

    I.E.Cock1,2*
    1Environmental Futures Research Institute, Nathan Campus, Griffith University, 170 Kessels Rd, Nathan, Brisbane, Queensland 4111, Australia.
    2School of Natural Sciences, Nathan Campus, Griffith University, 170 Kessels Rd, Nathan, Brisbane, Queensland 4111, Australia.

    Pharmacognosy Communications,2018,8,3,96
    DOI: 10.5530/pc.2018.3.20.
    Published: July 2018
    Type: Editorial

    ABSTRACT

    Dear Readers and Authors, I am pleased to bring you volume 8, issue 3 of Pharmacognosy Communications. In this issue we present new research examining the pharmacognosy of several important medicinal plants including the antibacterial and antifungal activity of the Asia medicinal plant Ajuga bracteosa. This species is used in a diverse array of Asian traditional medicine systems (including traditional Chinese medicine and Ayuverda) to treat a variety of inflammatory conditions including gout, rheumatism and amenorrhea. It has also been used for treatment of diabetes, malaria, and cancer. We also present a pharmacognostic study on Delonix regia. This species has an impressive range of medicinal and biological properties including uses for the treatment of constipation, inflammation, arthritis, hemiplagia, gynecological disorders, diabetes and rheumatism. An Indonesian study examined the phytochemistry of Myristica fragrans mace extracts and reported good antioxidant and antibacterial activity. Furthermore, the extracts inhibited α-glucosidase, indicating that they may also be useful in the treatment of diabetes. A further study examines the antioxidant properties of Mangifera indica leaves. We also present study which used an in silico docking model to highlight some phytochemicals with potential COX-2 and LOX-3 inhibitory potential. In particular, gallic acid and epicatechin were determined to be promising leads. Read more…

    Download PDF
    Share. Facebook Twitter Pinterest LinkedIn Tumblr WhatsApp Email
    About Journal
    About Journal

    Pharmacognosy Communications [Phcog Commn.] is a quarterly journal published by Phcog.Net. It is a peer reviewed journal aiming to publish high quality original research articles, methods, techniques and evaluation reports, critical reviews, short communications, commentaries and editorials of all aspects of medicinal plant research. The journal is aimed at a broad readership, publishing articles on all aspects of pharmacognosy, and related fields. The journal aims to increase understanding of pharmacognosy as well as to direct and foster further research through the dissemination of scientific information by the publication of manuscripts. The submission of original contributions in all areas of pharmacognosy are welcome.
    Indexed and Abstracted in : Chemical Abstracts, Excerpta Medica / EMBASE, Google Scholar, CABI Full Text, Ulrich’s International Periodical Directory, ProQuest, Journalseek & Genamics, PhcogBase, EBSCOHost, Academic Search Complete, Open J-Gate, SciACCESS.
    Rapid publication: Average time from submission to first decision is 30 days and from acceptance to In Press online publication is 45 days.
    Open Access Journal: Phcog Commn. is an open access journal, which allows authors to fund their article to be open access from publication.

    © 2025 Pharmacognosy Communications. Maintained by Manuscript TechnoMedia LLP.

    Type above and press Enter to search. Press Esc to cancel.

    Scroll Up